Physician profile
Robert S Gorab
NPI 1326035601
$13,572,447.93
in general payments reported to CMS, 2019-2025
8 companies · $1.9M in 2025
The $1.9M reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1.3M · 2020: $1.5M · 2021: $1.9M · 2022: $2.1M · 2023: $2.3M · 2024: $2.5M · 2025: $1.9M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $6.7M · Consulting Fee: $25K · Travel and Lodging: $1,760 · Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $6,723,138.37 |
| Consulting Fee | $25,149.60 |
| Travel and Lodging | $1,760.06 |
| Food and Beverage | $1,000.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Products, INC. | $13,470,403.28 | 2019-2025 | Attune, Actis, Sigma |
| Medical Device Business Services, INC. | $100,711.73 | 2019-2025 | Lcs, Attune, Sigma |
| Depuy Synthes Sales INC. | $638.49 | 2019-2025 | Inhance, Monovisc |
| Zimmer Biomet Holdings, INC. | $261.50 | 2021-2024 | Mymobility Platform |
| Smith+Nephew, INC. | $247.59 | 2024-2025 | Journey II, Real Intelligence |
| Pacira Pharmaceuticals Incorporated | $125.77 | 2023 | Iovera |
| Pacira Therapeutics, INC. | $38.15 | 2020 | |
| Bioventus LLC | $21.42 | 2023 | Durolane |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gorab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.